SecBot SecBot
SECBOTREPLAY Home › Report › BWAY

BWAY · BrainsWay presented positive real-world data showing 83.5% of comorbid…

BrainsWay · PRESS-RELEASE filed Jun 29, 2026 at 07:30 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 29, 2026 at 07:30 ET

BrainsWay presented positive real-world data showing 83.5% of comorbid PTSD/MDD patients responded to Deep TMS with a 52% mean symptom reduction. However, the therapy is not yet FDA-cleared for PTSD, limiting immediate commercial impact. The data strengthens the clinical evidence base but does not change near-term revenue or regulatory status.

  • 83.5% of 462 comorbid PTSD/MDD patients responded to Deep TMS (≥50% symptom reduction).
  • Mean PTSD symptom reduction of 52% (PCL-5).
  • 66.6% depression response rate, 27.3% remission rate, mean 50% PHQ-9 reduction.
  • Deep TMS is not yet FDA-cleared for PTSD; results are from a retrospective, real-world study.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access